Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/206275
Title: | Proposed Definitions of Antibody-Mediated Rejection for Use as a Clinical Trial Endpoint in Kidney Transplantation |
Author: | Roufosse, C. Becker, J. U. Rabant, M. Seron, D. Bellini, M. I. Böhmig, G. A. Budde, K. Diekmann, F. Glotz, D. Hilbrands, L. Loupy, A. Oberbauer, R. Pengel, L. Schneeberger, S. Naesens, M. |
Keywords: | Antígens HLA Rebuig (Biologia) HLA histocompatibility antigens Graft rejection |
Issue Date: | 20-May-2022 |
Abstract: | Antibody-mediated rejection (AMR) is caused by antibodies that recognize donor human leukocyte antigen (HLA) or other targets. As knowledge of AMR pathophysiology has increased, a combination of factors is necessary to confirm the diagnosis and phenotype. However, frequent modifications to the AMR definition have made it difficult to compare data and evaluate associations between AMR and graft outcome. The present paper was developed following a Broad Scientific Advice request from the European Society for Organ Transplantation (ESOT) to the European Medicines Agency (EMA), which explored whether updating guidelines on clinical trial endpoints would encourage innovations in kidney transplantation research. ESOT considers that an AMR diagnosis must be based on a combination of histopathological factors and presence of donor-specific HLA antibodies in the recipient. Evidence for associations between individual features of AMR and impaired graft outcome is noted for microvascular inflammation scores ≥2 and glomerular basement membrane splitting of >10% of the entire tuft in the most severely affected glomerulus. Together, these should form the basis for AMR-related endpoints in clinical trials of kidney transplantation, although modifications and restrictions to the Banff diagnostic definition of AMR are proposed for this purpose. The EMA provided recommendations based on this Broad Scientific Advice request in December 2020; further discussion, and consensus on the restricted definition of the AMR endpoint, is required.Copyright © 2022 Roufosse, Becker, Rabant, Seron, Bellini, Böhmig, Budde, Diekmann, Glotz, Hilbrands, Loupy, Oberbauer, Pengel, Schneeberger and Naesens. |
Note: | Reproducció del document publicat a: https://doi.org/10.3389/ti.2022.10140 |
It is part of: | TRANSPLANT INTERNATIONAL, 2022, vol. 35, p. 10140 |
URI: | http://hdl.handle.net/2445/206275 |
Related resource: | https://doi.org/10.3389/ti.2022.10140 |
ISSN: | 1432-2277 |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Proposed Definitions of Antibody-Mediated Rejection for Use as a Clinical Trial_TransplantInternational.pdf | 777.8 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License